Revolution Medicines secured $250 million in a new loan after FDA approval of RASONQUE™
Revolution Medicines, Inc. drew a Tranche A loan of $250.0 million under its senior secured credit facility on October 8, 2026, paying a one‑time draw fee of $5.0 million after FDA approval of RASONQUE™.
Key points
- The company entered a loan agreement with Wilmington Trust and Royalty Pharma Development Funding, LLC and received a Tranche A of $250.0 million on October 8, 2026, linked to FDA approval of RASONQUE™.
- The senior secured term loan provides up to three tranches of $250.0 million each, with interest paid quarterly in arrears; the principal of Tranche A is due on October 8, 2032.
- The funding was triggered by FDA approval of RASONQUE™ — a drug for treating metastatic pancreatic adenocarcinoma in adult patients.
What happened
The company entered a loan agreement with Wilmington Trust and Royalty Pharma Development Funding, LLC and received a Tranche A of $250.0 million on October 8, 2026, linked to FDA approval of RASONQUE™.
Key terms of Tranche A
Loan terms
The senior secured term loan provides up to three tranches of $250.0 million each, with interest paid quarterly in arrears; the principal of Tranche A is due on October 8, 2032.
Context
The funding was triggered by FDA approval of RASONQUE™ — a drug for treating metastatic pancreatic adenocarcinoma in adult patients.
What to watch
Key upcoming milestones are the quarterly interest payments set out in the loan agreement and the use of the $250.0 million, which will determine the company’s short‑term liquidity.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Revolution Medicines
A notification in your browser or on your phone when we publish about Revolution Medicines. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
